| 61.88 1.38 (2.28%) | 10-23 11:26 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 78.25 | 1-year : | 91.4 |
| Resists | First : | 67 | Second : | 78.25 |
| Pivot price | 56.37  |
|||
| Supports | First : | 48.76 | Second : | 37.5 |
| MAs | MA(5) : | 60.24 |
MA(20) : | 54.73 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 2.4 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 92.5 |
D(3) : | 90.5 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 67 | Low : | 6.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MENS ] has closed below upper band by 8.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 61.04 - 61.22 | 61.22 - 61.42 |
| Low: | 56.75 - 56.96 | 56.96 - 57.2 |
| Close: | 60.11 - 60.44 | 60.44 - 60.82 |
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases.
Sat, 26 Jul 2025
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain - Seeking Alpha
Tue, 01 Jul 2025
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Tue, 24 Jun 2025
Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech
Wed, 18 Jun 2025
Jyong Biotech Ltd. Closes $20 Million Initial Public Offering on Nasdaq - Nasdaq
Mon, 16 Jun 2025
Taiwan's Jyong Biotech Makes Nasdaq Debut: $20M IPO Targets Breakthrough in Urinary Disease Treatment - Stock Titan
Mon, 16 Jun 2025
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 62.2 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 130 (K) |
| Shares Short P.Month | 138 (K) |
| EPS | -0.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.51 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1567.75 |
| PEG Ratio | 0 |
| Price to Book value | -122.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -1317.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|